Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of MK0517 for PONV Prevention
NCT00231777Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2005
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of fosaprepitant in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Patients With Clinical Adverse Experiences (CAEs) and Number of Patients With Laboratory Adverse Experiences (LAEs). Started Jul 2005; status: completed.
02
Drugs
fosaprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT00231777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231777.